Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer

P. de Besi, V. C. Sileni, L. Salvagno, C. Tremolada, G. Cartei, V. Fosser, A. Paccagnella, A. Peracchia, M. Fiorentino

Research output: Contribution to journalArticlepeer-review

Abstract

Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response. Thirteen remissions (35%) were obtained, including three complete and ten partial, with a median duration of 9 months. After chemotherapy, seven responding patients underwent a surgical procedure, which was radical in four. The most frequent side effects were nausea and vomiting. This regimen is effective and can be included in a multimodality approach.

Original languageEnglish
Pages (from-to)909-910
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number7
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer'. Together they form a unique fingerprint.

Cite this